1FW

Page 1 of 3

## <u>IN THE UNITED STATES PATENT & TRADEMARK OFFICE</u>

In re application : SEYMOUR H. FEIN

Serial No. : 10/706,100

Filed: November 12, 2003

For : PHARMACEUTICAL COMPOSITIONS INCLUDING

LOW DOSAGES OF DESMOPRESSIN

Examiner

Attorney Docket : 102463-201

Group Art Unit : 1614
Confirmation No. : 7710
Customer No. : 27267

By

Todd E. Garabedian, Ph.D. Registration No. 39,197 Attorney for Applicant

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

[X] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- [] 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
  - a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
  - b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
  - Please charge Deposit Account No. <u>23-1665</u> in the amount of \$240.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
  - [] A check in the amount of \$240.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- [] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
  - [] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- [] Please charge Deposit Account No. <u>23-1665</u> in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. \$1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

SEYMOUR H. FEIN

Date: 20007 2004

: Todd E./N

Todd E. Garabedian, Ph.D. Registration No. 39,197 Attorney for Applicant

WIGGIN AND DANA LLP One Century Tower New Haven, CT 06508-1832

Telephone: (203) 498-4400 Telecopier: (203) 782-2889 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : SEYMOUR H. FEIN

Serial No. : 10/706,100

Filed: November 12, 2003

For : PHARMACEUTICAL COMPOSITIONS INCLUDING

LOW DOSAGES OF DESMOPRESSIN

Examiner

Attorney Docket : 102463-201

Group Art Unit : 1614 Confirmation No. : 7710 Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner

for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on 20 oct 2004

Todd E. Garabedian, Ph.D. Registration No. 39,197

Attorney for Applicant

SUPPLEMENTAL INFORMATION DISCLOSURE LETTER

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R.§ 1.56(b).

U. S. Application Serial No: 10/706,100 Attorney Docket No. 102463-201 Page 2 of 2

- 1. United States Patent No. 5,990,273 (ANDERSON, LUND L. H. H., and SKOLDBACK, MALMO J.) 23 November 1999 (1999-11-23).
- 2. United States Patent No. 5,985,835 (LARSSON, KRISTER, ET AL.) 16 November 1999 (1999-11-16).
- 3. United States Patent No. 5,500,413 (LARSSON, KRISTER, ET AL.) 19 March 1996 (1996-03-19).
- 4. United States Patent No. 4,285,858 (CORT, JOSEPH H. and FISCHMAN, ALAN) 25 August 1981 (1981-08-25).

Applicant submits that copies of the above-cited references are enclosed herewith.

If the Examiner has any questions or feels that a discussion with Applicant's representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicant's undersigned representative at the telephone number listed below.

Respectfully submitted,

SEYMOUR H. FEIN

Date: 20 OCT 2004

Todd E. Garabedian, Ph.D.

Registration No. 39,197 Attorney for Applicant

WIGGIN AND DANA LLP One Century Tower P. O. Box 1832

New Haven, CT 06508-1832 Telephone: (203) 498-4400

Fax:

(203) 782-2889

\12985\2\93665.1

## FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT WAPPECANT			ATTY. DOCKET NO. 102463-201			SERIAL NO. 10/706,100	
			APPLICANT: SEYMOUR H. FEIN				
OCT 2 2 2004 &			FILING DATE: NOVEMBER 12, 2003			GROUP: 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPR.
	5,990,273	11/23/1999	Anderson, L.L.H.H.	et al.	C07K	1/02	
	5,985,835	11/16/1999	Larsson, K., et al.		A61K	38/00	·
	5,500,413	03/19/1996	Larsson, K., et al.		A61K	38/00	
	4,285,858	08/25/1981	Cort, J.H., et al.		C07C	103/52	
		_					
							-
					<del></del>		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLAS	SS	SUBCLASS	TRANSLATION Yes No
<u> </u>							
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
•						<del></del>	
EXAMINER:			DATE CONSIDERED:				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							